论文部分内容阅读
RIGHT研究(The ceRIvastatin Gemfibrozil Hyperlipi-demia Treatment):一项多中心、随机、双盲、安慰剂对照研究,比较了拜斯亭0.1mg,0.2mg,0.3mg每日1次和吉非罗齐600mg每日2次治疗751例原发性混合型高脂血症患者的作用。 经过开始4周的清洗阶段,再经过6周饮食控制和单盲安慰剂治疗入选阶段后,患者随机入选拜斯亭0.1mg,0.2mg,0.3mg,吉非罗齐1200mg或安慰剂组,共治疗52周。在第36周时,对LDL-C不能控制的患者加用消胆胺。 第16周时,0.1mg、0.2mg、0.3mg拜斯亭分别降低低密度脂蛋白胆固醇(LDL-C)15.1％、23.0％和24.2％,而吉非罗齐降低7.5％。
RIGHT Study (The ceRIvastatin Gemfibrozil Hyperlipi-demia Treatment): A multicenter, randomized, double-blind, placebo-controlled study comparing Besite 0.1 mg, 0.2 mg, 0.3 mg once daily and gemfibrozil 600 mg Treatment of 751 patients with primary mixed hyperlipidemia twice daily. After the initial 4-week washout phase, followed by a 6-week diet-controlled and single-blind placebo-treatment phase, patients were randomized to beitin 0.1 mg, 0.2 mg, 0.3 mg, gemfibrozil 1200 mg, or placebo Treatment for 52 weeks. Cholestyramine is added to patients who can not control LDL-C at week 36. At week 16, 0.1 mg, 0.2 mg, 0.3 mg bevacizin reduced 15.1%, 23.0%, and 24.2%, respectively, of low density lipoprotein cholesterol (LDL-C), while gemfibrozil decreased by 7.5%.